MNPR Monopar Therapeutics Inc.

QT24

Latest market price

66.28

-4.04-5.75%

Overview Short InterestFilings

MNPRQT24Monopar Therapeutics Inc.·NASDAQ

Overview Short InterestFilings

66.28-5.75%

News

Down 5.7% — Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.34	Insider Own	41.18%	Shs Outstand	6.71M	Perf Week	-6.04%

Market Cap	444.88M	Forward P/E	—	EPS next Y	-2.46	Insider Trans	-1.88%	Shs Float	3.94M	Perf Month	-14.99%

Enterprise Value	310.88M	PEG	—	EPS next Q	-0.86			Short Float	28.66%	Perf Quarter	-44.05%

Income	-17.00M	P/S	—	EPS this Y	—			Short Ratio	5.49	Perf Half Y	21.30%

Sales	0.00	P/B	3.40	EPS next Y	—	ROA	-13.22%	Short Interest	1.13M	Perf YTD	1.50%

Book/sh	19.52	P/C	3.32	EPS next 5Y	—	ROE	-13.08%	52W High	124.82 -46.90%	Perf Year	-22.63%

Cash/sh	19.96	P/FCF	—	EPS past 3/5Y	—	ROIC	-16.89%	52W Low	50.07 32.37%	Perf 3Y	2982.79%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	5.78% 5.26%	Perf 5Y	188.80%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	4.12	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	33.56	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	28.69	Recom	2.21

Dividend Gr. 3/5Y	—	Current Ratio	33.56	EPS Q/Q	-77.14%	SMA20	-10.14%	Beta	1.56	Target Price	126.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	-26.56%	Rel Volume	1.31	Prev Close	70.32

Employees	22	LT Debt/Eq	0.00	Earnings	Nov 12	SMA200	-14.17%	Avg Volume	167.35K	Price	66.28

IPO Date	Dec 19, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	4.19% —	Net Debt/EBITDA	—	Volume	218,899	Change	-5.75%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-11-26	Reiterated	Barclays	Overweight	$128 → $145
Aug-17-26	Reiterated	Morgan Stanley		$115 → $130
Aug-13-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$119
Aug-13-26	Reiterated	Barclays	Overweight	$125 → $128
Aug-12-26	Reiterated	BTIG	Buy	$117 → $133
Jul-23-26	Reiterated	UBS		$105 → $125
Jul-22-26	Reiterated	HC Wainwright & Co.	Buy	$105 → $125
Jun-30-26	Reiterated	BTIG	Buy	$104 → $117
Jun-29-26	Reiterated	UBS		$37 → $105
Jun-02-26	Reiterated	Piper Sandler	Overweight	$95 → $105

Latest News· Times ET

Nov-02-26

Nov-02-2608:00AM

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Dataglobenewswire.com

Sep-11-26

Sep-11-2605:48AM

Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145Benzinga

Aug-24-26

Aug-24-2603:59AM

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrastdefenseworld.net

Aug-19-26

Aug-19-2608:00AM

Monopar Appoints Jeffrey D. Kent, M.D.globenewswire.com

Aug-18-26

Aug-18-2607:45AM

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'SeekingAlpha

Aug-13-26

Aug-13-2607:53AM

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More247wallst.com

Aug-12-26

Aug-12-2609:30AM

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.com

Aug-11-26

Aug-11-2602:06PM

Prime Medicine: An Initial PrognosisSeekingAlpha

Jul-22-26

Jul-22-2608:00AM

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Diseaseglobenewswire.com

07:59AM

HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125Benzinga

Jul-20-26

Jul-20-2608:00AM

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Teamglobenewswire.com

Jul-16-26

Jul-16-2611:58PM

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)SeekingAlpha

Company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	1,744	6,800	3	3	—	—	—	—	—
Research and Development	15	9,904	13	6	—	—	—	—	—
Other Operating Expense	-1,737	-16,687	0	0	—	—	—	—	—
Operating Income	-22	-17	-16	-9	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	3	1	0	—	—	—	—	—
Net Income Before Taxes	-17	-14	-16	-8	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-17	-14	-16	-8	—	—	—	—	—
Net Income From Continuing Operations	-17	-14	-16	-8	—	—	—	—	—
Net Income	-17	-14	-16	-8	—	—	—	—	—
EPS (Recurring)	-2.34	-1.85	-1.36	-0.58	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.34	-1.85	-1.36	-0.58	—	—	—	—	—
EPS (Diluted)	-2.34	-1.85	-1.36	-0.58	—	—	—	—	—
EBITDA	-18	-14	-16	-8	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	9	7	11	15	—	—	—	—	—
Market Capitalization	597	457	242	26	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STARR CHRISTOPHER M	Director	Oct 01 '26	Option Exercise	0.01	8,400	42	13,573	Oct 05
STARR CHRISTOPHER M	Director	Oct 01 '26	Sale	78.50	8,400	659,386	5,173	Oct 05
Robinson Chandler	Chief Executive Officer	Sep 30 '26	Option Exercise	0.00	9,801	0	109,068	Oct 02
Vu Quan Anh	Chief Financial Officer	Sep 30 '26	Option Exercise	0.00	614	0	2,835	Oct 02
Cittadine Andrew	Chief Operating Officer	Sep 30 '26	Option Exercise	0.00	4,384	0	59,998	Oct 02
Robinson Chandler	Chief Executive Officer	Sep 24 '26	Option Exercise	21.74	29,056	631,680	128,323	Sep 28
Robinson Chandler	Chief Executive Officer	Sep 24 '26	Sale	88.00	29,056	2,556,851	99,267	Sep 28
Tsuchimoto Kim R	Director	Aug 26 '26	Option Exercise	22.04	8,180	180,280	8,140	Aug 28
Tsuchimoto Kim R	Director	Aug 26 '26	Sale	111.39	8,180	911,134	0	Aug 28
Anderson Raymond	Director	Aug 25 '26	Option Exercise	30.00	6,284	188,520	8,515	Aug 28
Anderson Raymond	Director	Aug 25 '26	Sale	111.88	6,284	703,024	5,373	Aug 28
RIOUX PATRICE	Acting Chief Medical Officer	Aug 26 '26	Option Exercise	0.01	2,760	14	5,066	Aug 27
RIOUX PATRICE	Acting Chief Medical Officer	Aug 26 '26	Sale	111.26	1	111	5,065	Aug 27
Vu Quan Anh	Chief Financial Officer	Jun 30 '26	Option Exercise	0.00	1,228	0	2,728	Jul 02
Robinson Chandler	Chief Executive Officer	Jun 30 '26	Option Exercise	0.00	12,873	0	103,351	Jul 02

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.